Funding biotech start-ups in a post-VC world
Requires Subscription or Fee PDF


venture capital
business angel


Investment in start-up biotech. companies outside the USA has essentially disappeared. VC investment in biotechnology and healthcare as a whole has nearly returned to pre-2008 levels, but almost all is in later stage opportunities. But companies continue to be founded, and continue to flourish. We examine the VC investment patterns for the past 7 years, and show that a start-up today can expect little VC support. We show from companies’ financial records that companies are adopting financial models based on angel investment, grants and revenue, and moving away from business models that need substantial investment. There is a time lag, but government and research council policy is beginning to recognize and align with the new investment realities. We believe this trend will accelerate as internet-mediated angel investing, such as crowd-funding schemes seen in other sectors, become a developing force in the next decade.
Requires Subscription or Fee PDF


UKTI. (2008) Bioscience UK. London: UK Trade and InvestmentMarch 2008.

Lawrence S. (2007) Upward Trend in financing continues, but fewer feel flush. Nature Biotechnology.25(1):3.

Lee D.P., Dibner M.D. (2005) The rise of venture capital and biotechnology in the US and Europe. Nature Biotechnology.23(6):672 - 6.

Browning J. (2009) The incredible shinking venture capital. Nature 460:459.

Huggett B., Lähteenmaki R. (2012) Public biotech 2011 - by the numbers. Nature Biotechnology.30:751 - 7.

Cambridge Associates LLC. (2011) Cambridge Associates LLC U. S. Venture Capital Index and selected benchmark statistics. Boston, MA: National Venture Capital Association.

Booth B.I., Salehizadeh B. (2011) In defence of life science venture investing. Nature Biotechnology.29(7):579 - 83.

Bains W. (2008) Venture capital and the european biotechnology industry. Basingstoke, UK: Palgrave Macmillan

Mulcahy D., Weeks B., Bradley H.S. (2012) We have met the enemy ... and he is us. Lessons from twenty years of the Kauffman Foundation's investments in Venture Capital Funds and the triumph of hope over experience. Kansas City, MO: Ewing Marion Kauffmann Foundation.

Lash A., Salemi T. Venture capital survey paints bleak portrait. The Pink Sheet. 2012:17 - 9.

Karus. (2012) Karus Therapeutics Secures Series B Financing from a Syndicate of Leading VC Investors. 2012 [19th October 2012]; Available from:

Mission. (2011) £6M Secured in series-a-funding. 2011; Available from:

Buch H.K., Gustafsson A., Drvota V., Sundberg C.J. (2011) Divining the path to a successful European exit. Nature Biotechnology.29(3):205 - 7.

Wooder S. (2012) Funding Sources & Outcomes for Cambridge Area Biotechnology Companies. Cambridge.

British Venture Capital Association. (2008) Venture Capital Manifesto. London, UK: BVCA.

Bioscience Innovation and Growth Team. (2009) The Review and Refresh of Bioscience 2015. London: Bioindustry Association Contract No.: BERR/Pub 8811/0.4k/01/09/NP. URN 09/517.

Bioscience Innovation and Growth Team. (2003) Bioscience 2015. London: Bioindustry Association Contract No.: DTI/Pub 6988/1k/11/03/NP. URN 03/1321.

Bains W. (2009) The VC manifesto: special pleading for a damaged cause. Journal of Commercial Biotechnology.15:290 - 2.

Hugo E., Franklin R., Coffman C., Lawton J., Holi M., van Leeuwen M., White R., Harper D. (2007) Looking Inwards, Reaching Outwards The Cambridge Cluster Report – 2007. Cambridge, UK: Library House.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.